Press coverage about Celldex Therapeutics (NASDAQ:CLDX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Celldex Therapeutics earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.5554748736371 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment’s rankings:
- Celldex Therapeutics (CLDX) Given Hold Rating at Jefferies Financial Group (americanbankingnews.com)
- Cowen Reiterates Hold Rating for Celldex Therapeutics (CLDX) (americanbankingnews.com)
- Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Celldex: 2Q Earnings Snapshot (finance.yahoo.com)
- Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates (finance.yahoo.com)
A number of brokerages have weighed in on CLDX. BidaskClub raised Celldex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 14th. HC Wainwright set a $3.00 price target on Celldex Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 16th. Cowen cut Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, April 16th. ValuEngine raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Finally, Cantor Fitzgerald cut Celldex Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a research report on Tuesday, April 17th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $3.75.
Shares of NASDAQ:CLDX traded down $0.02 on Friday, reaching $0.43. The company had a trading volume of 1,413,369 shares, compared to its average volume of 1,318,902. Celldex Therapeutics has a twelve month low of $0.41 and a twelve month high of $3.26. The stock has a market capitalization of $72.32 million, a P/E ratio of -0.53 and a beta of 2.36.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. Celldex Therapeutics had a negative return on equity of 47.40% and a negative net margin of 1,159.26%. The company had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $2.70 million. equities analysts forecast that Celldex Therapeutics will post -0.51 earnings per share for the current fiscal year.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Featured Story: Diversification in Your Portfolio
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.